MaaT Pharma Welcomes Dr. Gianfranco Pittari As Chief Medical Officer

MaaT Pharma (EURONEXT: MAAT), a biotechnology company specializing in Microbiome Ecosystem TherapiesTM (MET) for cancer patients, has appointed Gianfranco Pittari, M.D., Ph.D., as Chief Medical Officer. Dr. Pittari, with more than 15 years of global expertise in clinical research and drug development in hematology, oncology, and immunology, will join the executive leadership team. In his new role, he will be responsible for managing the clinical programs of the innovative microbiome-derived drug candidates of the company.

Hervé Affagard, Chief Executive Officer and co-founder of MaaT Pharma, said in a statement, “We are very pleased to welcome Gianfranco to MaaT Pharma. With his extensive experience leading clinical studies from early development through late-stage trials, he is a valuable addition to MaaT Pharma’s team during this critical period of growth as our lead asset, MaaT013, nears Phase 3 trial completion. Dr. Pittari’s international background strengthens our growing global team, reinforcing our expertise to excel in serving patients worldwide.”

Dr. Pittari possesses significant medical expertise in drug development, focusing extensively on oncology and hematology. His professional background involves overseeing effective Phase I-III clinical trials at Celgene Corporation - Bristol Myers Squibb. He played a pivotal role in advancing the initial CAR T cell therapy for Multiple Myeloma (known as Abecma® or idecabtagene vicleucel), which is currently approved in the US and EU for earlier treatment stages in patients experiencing relapsed and refractory disease.

Prior to his tenure at MaaT Pharma, he held the role of Executive Medical Director at Autolus, a clinical-stage biopharmaceutical company specializing in next-generation, programmed T Cell therapies for cancer and autoimmune disorders. Additionally, he served as Senior Consultant in Hematology-BMT at the National Center for Cancer Care and Research in Qatar. This institution is renowned globally for its advanced clinical care and academic contributions, where he focused on treating patients with hematological disorders and contributed to numerous academic initiatives.

Dr. Pittari, Chief Medical Officer, stated “I am inspired by MaaT Pharma’s ambition and vision to serve physicians and bring innovative treatments to patients with high unmet needs in oncology. I look forward to bringing my experience to support the team and contributing to the advancement of our microbiome drug candidates to help patients with cancer.”